What's Happening?
Gilead Sciences and Arcus Biosciences have decided to terminate a late-stage study of their investigational TIGIT drug, domvanalimab, due to a lack of efficacy in treating metastatic non-small cell lung cancer (NSCLC). The decision follows an independent
data panel's assessment that the drug's performance was futile compared to Merck's Keytruda plus chemotherapy. This move also leads to the discontinuation of the Phase 2 EDGE-Lung study of domvanalimab in NSCLC. Gilead will not continue its option payments, effectively ending its access to early-stage TIGIT therapies from Arcus. Despite this setback, Gilead retains options on other Arcus programs, including the AXL blocker AB801 and the anti-CD39 antibody AB598. The collaboration between Gilead and Arcus, initiated in 2020, aimed to develop next-generation cancer therapies, but has faced challenges as other TIGIT programs have also struggled.
Why It's Important?
The discontinuation of these trials highlights the challenges faced by pharmaceutical companies in developing effective cancer treatments, particularly in the competitive field of immuno-oncology. The decision impacts Gilead's strategic positioning in the cancer therapy market and underscores the financial risks associated with high-stakes drug development. The broader implications for the biotech industry include potential shifts in investment strategies as companies reassess the viability of TIGIT-targeted therapies. This development may influence future research directions and collaborations within the sector, as companies seek to mitigate risks and optimize resource allocation.
What's Next?
Gilead's decision to halt further investment in the TIGIT program with Arcus may lead to a reevaluation of its oncology pipeline and strategic partnerships. The company might focus on other promising areas within its portfolio or seek new collaborations to bolster its cancer treatment offerings. For Arcus, the end of this collaboration could prompt a strategic pivot to other therapeutic areas or partnerships. The broader industry may witness a shift in focus from TIGIT therapies to alternative immuno-oncology targets, as companies aim to capitalize on emerging scientific insights and technological advancements.
